- Patients
- Clinical Research
- Clinical trials
- SHERLOCK
Lung Cancer
SHERLOCK
Sotorasib witH bEvacizumab fiRst Line cOmbined with Chemotherapy for KRAS G12C NSCLC (SHERLOCK CTC 0377 / TOGA 21/011) Phase 2 trial of sotorasib in combination with carboplatin-pemetrexed and bevacizumab-biosimilar as first line treatment for advanced non-squamous non-small cell lung cancer with KRAS G12C mutation
Trial overview
Medical Oncology
Lung
II
Registration number: ACTRN12622000973718
https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12622000973718
North Shore
North Shore Health Hub, Tower A, Level 1, 7 Westbourne St, St Leonards, NSW, 2065, Australia
(02) 8037 4100 admin.northshore@genesiscare.comMedical Oncologist
Prof. Nick Pavlakis
BSc MBBS MMed PhD FRACP
Frenchs Forest (Oncology) +1
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.